RECRUITING

Molecular Autopsy Study

Conditions

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This study seeks to incorporate genetic testing into the postmortem examination of cases of sudden unexplained death.

Official Title

Molecular Autopsy for Sudden Cardiovascular Death

Quick Facts

Study Start:2014-06

Study Completion:2030-06

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT02168088

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:Not specified to 45 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:CHILD, ADULT

Inclusion Criteria	Exclusion Criteria
* Index case age between birth - 45 years * Clinical presentation of sudden / unexplained death (believed to be cardiac in nature OR secondary to a massive unprovoked pulmonary embolism with no prior diagnosis of prothrombotic disease)	* Premature death secondary to murder, suicide or external causal event * Premature death thought secondary to known chronic comorbid medical condition * Premature death thought secondary to end-organ failure (kidney, liver, lung) other than heart * Previously diagnosed with hypertrophic cardiomyopathy (HCM) * Prior myocardial infarction (regardless of stenting or bypass) * Prior cerebrovascular accident (stroke or TIA) * History of open heart surgery (for any reason) * History of severe, untreated hypertensive heart disease * History of illicit drug use * History of heavy alcohol abuse * History of severe pulmonary disease * History of morbid obesity

Inclusion Criteria

Exclusion Criteria

* Index case age between birth - 45 years
* Clinical presentation of sudden / unexplained death (believed to be cardiac in nature OR secondary to a massive unprovoked pulmonary embolism with no prior diagnosis of prothrombotic disease)

* Premature death secondary to murder, suicide or external causal event
* Premature death thought secondary to known chronic comorbid medical condition
* Premature death thought secondary to end-organ failure (kidney, liver, lung) other than heart
* Previously diagnosed with hypertrophic cardiomyopathy (HCM)
* Prior myocardial infarction (regardless of stenting or bypass)
* Prior cerebrovascular accident (stroke or TIA)
* History of open heart surgery (for any reason)
* History of severe, untreated hypertensive heart disease
* History of illicit drug use
* History of heavy alcohol abuse
* History of severe pulmonary disease
* History of morbid obesity

Contacts and Locations

Study Contact

Sarah Topol, RN

CONTACT

858-784-2155

topol.sarah@scrippshealth.org

Emily Spencer, Phd

CONTACT

858-784-2029

egspence@scripps.edu

Study Locations (Sites)

Scripps Translational Science Institute

La Jolla, California, 92037

United States

Collaborators and Investigators

Sponsor: Scripps Translational Science Institute

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2014-06

Study Completion Date2030-06

Study Record Updates

Study Start Date2014-06

Study Completion Date2030-06

Terms related to this study

Keywords Provided by Researchers

Sudden unexplained death

Additional Relevant MeSH Terms

Sudden Unexplained Death